Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAXNASDAQ:CVACNASDAQ:ELVNNASDAQ:GNFT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$9.27-40.8%$12.91$7.80▼$28.09$505.55MN/A532,519 shs7.20 million shsCVACCureVac$4.09-1.7%$3.24$2.37▼$5.28$917.54M2.43753,618 shs755,856 shsELVNEnliven Therapeutics$16.40-2.2%$18.46$13.30▼$30.03$822.89M1.07259,466 shs222,508 shsGNFTGenfit$4.23-2.5%$3.75$2.55▼$6.42$211.48M0.9214,744 shs4,264 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics-40.80%-35.94%-40.23%-28.69%+926,999,900.00%CVACCureVac-1.68%+9.95%+28.41%+23.94%+4.60%ELVNEnliven Therapeutics-2.21%-2.73%-7.71%-24.77%-28.35%GNFTGenfit-2.53%+0.95%+16.18%+11.17%-4.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCAXBicara Therapeutics1.6377 of 5 stars3.40.00.00.01.80.80.6CVACCureVac3.57 of 5 stars3.51.00.04.81.70.01.3ELVNEnliven Therapeutics2.4752 of 5 stars3.62.00.00.01.94.20.0GNFTGenfit0.9609 of 5 stars3.52.00.00.00.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCAXBicara Therapeutics 3.00Buy$31.86243.67% UpsideCVACCureVac 3.00Buy$14.00242.30% UpsideELVNEnliven Therapeutics 3.20Buy$37.25127.13% UpsideGNFTGenfit 3.00Buy$13.00207.33% UpsideCurrent Analyst Ratings BreakdownLatest GNFT, CVAC, BCAX, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025BCAXBicara TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$8.005/23/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.005/16/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $41.005/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/15/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.004/30/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.004/17/2025BCAXBicara TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderweight$8.004/7/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $44.003/27/2025BCAXBicara TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$48.003/27/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$31.003/21/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $39.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCAXBicara TherapeuticsN/AN/AN/AN/AN/AN/ACVACCureVac$535.18M1.71N/AN/A$2.50 per share1.64ELVNEnliven TherapeuticsN/AN/AN/AN/A$5.97 per shareN/AGNFTGenfit$67.00M3.16N/AN/A$1.48 per share2.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCAXBicara TherapeuticsN/AN/A0.00N/AN/AN/AN/AN/A6/26/2025 (Estimated)CVACCureVac-$281.58M$0.827.44N/AN/A20.72%21.98%15.72%N/AELVNEnliven Therapeutics-$71.58M-$1.92N/AN/AN/AN/A-29.46%-27.33%8/12/2025 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/AN/ALatest GNFT, CVAC, BCAX, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025CVACCureVac-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/13/2025Q1 2025BCAXBicara Therapeutics-$0.40-$0.68-$0.28-$0.68N/AN/A4/10/2025Q4 2024CVACCureVac-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million3/27/2025Q4 2024BCAXBicara Therapeutics-$0.31-$0.39-$0.08-$0.39N/AN/A3/13/2025Q4 2024ELVNEnliven Therapeutics-$0.53-$0.46+$0.07-$0.46N/A$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCAXBicara TherapeuticsN/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCAXBicara TherapeuticsN/AN/AN/ACVACCureVac0.056.206.19ELVNEnliven TherapeuticsN/A17.4417.44GNFTGenfit0.613.743.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCAXBicara TherapeuticsN/ACVACCureVac17.26%ELVNEnliven Therapeutics95.08%GNFTGenfit2.24%Insider OwnershipCompanyInsider OwnershipBCAXBicara Therapeutics15.50%CVACCureVac2.15%ELVNEnliven Therapeutics29.20%GNFTGenfit4.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCAXBicara Therapeutics3254.54 millionN/AN/ACVACCureVac880224.34 million219.07 millionOptionableELVNEnliven Therapeutics5049.07 million34.59 millionOptionableGNFTGenfit12050.00 million47.90 millionNot OptionableGNFT, CVAC, BCAX, and ELVN HeadlinesRecent News About These CompaniesGENFIT S.A.: GENFIT Reports First Quarter 2025 Financial InformationMay 23 at 7:34 AM | finanznachrichten.deGENFIT Reports First Quarter 2025 Financial InformationMay 22 at 4:10 PM | globenewswire.comGENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in ItalyMay 20, 2025 | globenewswire.comGENFIT S.A.: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)May 15, 2025 | finanznachrichten.deGENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)May 14, 2025 | globenewswire.comGenfit: Iqirvo's Success Can't Outweigh ACLF Pipeline RisksMay 12, 2025 | seekingalpha.comGenfit (NASDAQ:GNFT) Trading Up 2% - Still a Buy?May 9, 2025 | marketbeat.comGENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory DocumentsMay 7, 2025 | globenewswire.comGENFIT to Present Latest ACLF Research at EASL Congress 2025May 5, 2025 | globenewswire.comGENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-FApril 29, 2025 | globenewswire.comGENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025April 28, 2025 | globenewswire.comGENFIT S.A.: GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate UpdateApril 25, 2025 | finanznachrichten.deGENFIT Reports Full-Year 2024 Financial Results and Provides Corporate UpdateApril 24, 2025 | globenewswire.comGENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holdersMarch 20, 2025 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for WeekMarch 14, 2025 | msn.comRoyalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEsMarch 10, 2025 | globenewswire.comGENFIT Announces Revenues and Cash Position as of December 31, 2024February 27, 2025 | globenewswire.comGENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meetingFebruary 21, 2025 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday TradingFebruary 18, 2025 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Up 1% for WeekFebruary 14, 2025 | msn.comGENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs HoldersFebruary 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNFT, CVAC, BCAX, and ELVN Company DescriptionsBicara Therapeutics NASDAQ:BCAX$9.27 -6.39 (-40.80%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.20 -0.07 (-0.76%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.CureVac NASDAQ:CVAC$4.09 -0.07 (-1.68%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.15 +0.06 (+1.56%) As of 05/23/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Enliven Therapeutics NASDAQ:ELVN$16.40 -0.37 (-2.21%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$16.38 -0.02 (-0.12%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Genfit NASDAQ:GNFT$4.23 -0.11 (-2.53%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$4.64 +0.41 (+9.67%) As of 05/23/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
